MTHFR gene variants, what the research actually says (versus what wellness influencers say)

If you've spent any time in the wellness or biohacker corners of the internet, you've heard about MTHFR. The gene shows up in supplement marketing, in "methylation panel" interpretations, in fatigue and mood discussions, and in pregnancy-loss communities. The claims around it range from "you need methylfolate, not folic acid" (mostly defensible) to "your MTHFR variant explains your depression / autism / cardiovascular disease / chronic fatigue" (much weaker).

This post is the MTHFR gene variant explained from a research-anchored angle: what the literature supports, what it doesn't, and what someone with an MTHFR variant should reasonably do about it. Call it anti-grift genetics if you want. We call it the baseline.

What MTHFR is

MTHFR (methylenetetrahydrofolate reductase) is an enzyme central to folate metabolism. It converts 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate, which is the active form of folate used in methylation reactions, including the methylation of homocysteine into methionine, which is in turn needed for SAM-e production and a long list of downstream methylation reactions.

The two most-discussed variants are:

• rs1801133 (C677T, also called A222V): the more clinically significant of the two. The T allele produces a thermolabile, lower-activity enzyme. Homozygotes (TT) have 30-40% of reference enzyme activity. Heterozygotes (CT) have about 60-65%. For the MTHFR C677T meaning at the DNA level, see the dbSNP record for rs1801133.
• rs1801131 (A1298C, E429A): less impactful. The C allele has a smaller effect on enzyme function. CC homozygotes are common in the general population. The MTHFR A1298C meaning is summarized at dbSNP rs1801131.

About 10-15% of people of European ancestry are TT for rs1801133. About 40% are CT. The variants are similarly common in some other populations, less common in others. For population-level association data across cardiovascular, neural tube, and homocysteine phenotypes, the NHGRI-EBI GWAS Catalog entry for MTHFR is the canonical browse.

What's well-established

A handful of claims about MTHFR are reasonably well-supported by the literature:

Homocysteine levels are modestly elevated in TT carriers, especially with low folate intake. Multiple meta-analyses (Klerk et al. 2002, Wald et al. 2002, others) show consistent association. The effect is amplified when dietary folate is low, since the impaired enzyme has less substrate to work with.

TT homozygotes benefit more from folate supplementation than from folic acid alone. Folic acid (the synthetic form in fortified foods and most supplements) requires conversion by the same MTHFR enzyme that's impaired. Methylfolate (the active form, 5-MTHF) bypasses that conversion. Several RCTs show that TT carriers reach optimal folate status more reliably with methylfolate than with folic acid at equivalent doses.

Adequate folate intake matters more for TT carriers during pregnancy. This is the genuinely consequential clinical finding. Inadequate folate during conception elevates neural tube defect risk, and the elevation is somewhat greater in MTHFR TT mothers. Standard prenatal recommendations are higher for TT carriers, and methylfolate is often preferred over folic acid.

These three claims are evidence-anchored. They survive replication. They appear in standard clinical references. If you want to read the primary literature directly, the PubMed MTHFR C677T search is a reasonable starting point, and PharmGKB's MTHFR gene page catalogs the pharmacogenomic annotations (mostly methotrexate and 5-fluorouracil response). For clinically classified variants, ClinVar's MTHFR query shows what the curated medical-genetics community actually flags as pathogenic versus benign, which is a useful sanity check when an influencer calls a common polymorphism a "mutation."

What's overclaimed

A much longer list of claims has been attached to MTHFR by the consumer genetics community without solid support:

"MTHFR explains your depression." The link between elevated homocysteine and depression exists but is weak; the link between MTHFR variants and depression is weaker still. Multiple large meta-analyses (Gilbody et al. 2007, Wu et al. 2013) found small effect sizes that often don't survive multiple-testing correction. Treating depression as an MTHFR problem usually means missing the much-bigger contributors to mood disorders.

"MTHFR causes cardiovascular disease." The mechanism (homocysteine → vascular damage) is plausible. The actual elevated risk for TT carriers in well-controlled studies is small (relative risk around 1.15-1.20 for coronary heart disease, per the MTHFR Studies Collaboration analysis of >40,000 cases). For comparison, traditional cardiovascular risk factors like LDL cholesterol or hypertension have effect sizes several times larger.

"MTHFR causes autism / ADHD / chronic fatigue." These claims circulate widely but the evidence is thin. Where association studies exist, the effect sizes are small, replication is inconsistent, and the populations and methodologies are usually narrow. The much-stronger predictor of these conditions is family history, not MTHFR status.

"Folic acid is toxic to MTHFR carriers." This one is particularly common in wellness content and is wrong. Folic acid is converted less efficiently in TT carriers but is not toxic. The accurate framing is "methylfolate is more efficient, especially at higher doses." Whether this matters for any one person depends on their dietary folate intake.

"You need a methylation supplement stack." The methylation pathway involves many enzymes and many cofactors. MTHFR is one of them. Marketing a stack of B12, B6, B2, magnesium, choline, betaine, and methylfolate as "the MTHFR protocol" overgeneralizes from one variant to an entire biochemical pathway. Some of those cofactors matter; some don't; the right answer depends on the rest of someone's profile and intake, not on MTHFR status alone.

What's specifically misleading about online MTHFR reports

If you've run your raw data through Genetic Genie or one of the methylation-focused reports, the result usually shows you several variants alongside MTHFR, MTRR, MTR, CBS, COMT, BHMT, AHCY, and frames them as a "methylation panel" where multiple "mutations" compound to produce broad dysfunction.

This framing has two problems:

• "Mutation" is the wrong word. Common variants (allele frequency above 1%) are not mutations in the technical sense, they're normal variation in the human genome. Mutations are rare, often pathogenic, and usually identified through clinical testing. Most "methylation panel" findings are common variants.
• The compounding logic doesn't survive testing. When you stack five common variants each of small effect, the predicted compounding effect rarely shows up in well-controlled studies. The interactions are complex, dose-dependent, and often dominated by environmental factors (dietary folate, B12 status, smoking, alcohol) more than by genotype.

The honest reading of a methylation panel for most carriers is: pay attention to MTHFR if your homocysteine is elevated or you're planning pregnancy; the other variants are interesting but generally don't justify specific interventions.

What to actually do if you carry MTHFR TT or CT

The boring, evidence-supported stuff:

1. Eat enough folate. Leafy greens, legumes, citrus. Roughly 400 mcg dietary folate equivalents per day for most adults, more during pregnancy.
2. If supplementing, consider methylfolate over folic acid. Especially at TT homozygous status. Standard doses (400-800 mcg of L-5-MTHF or L-methylfolate) are well-tolerated and effective.
3. Check homocysteine if you haven't. A standard lab test ($30-50). If elevated (>10 µmol/L is a common reference threshold; >15 is clearly elevated), discuss with a physician. Treatment usually involves B vitamins and folate; the response varies.
4. For pregnant or trying-to-conceive women: discuss prenatal supplementation with an obstetrician. The standard recommendation is at least 400 mcg folate (often as folic acid; methylfolate is reasonable as an alternative). TT homozygotes are sometimes advised to take higher doses.

The not-evidenced stuff to skip:

• High-dose B12 / B6 / B2 / TMG / SAM-e stacks marketed specifically for MTHFR. Most don't have RCT evidence for routine use.
• Avoiding folic acid in fortified foods (the elevation in unmetabolized folic acid is real but the clinical significance is unclear and folate deficiency is much more clearly harmful).
• "Genetic detox" protocols that claim to address MTHFR-related toxin sensitivity. The phase-I and phase-II detoxification systems are unrelated to MTHFR's role.

How Expressive handles MTHFR

If you upload your raw genetic file to Expressive, we surface MTHFR rs1801133 and rs1801131 with the evidence quality flagged explicitly: strong for homocysteine effect, moderate for pregnancy folate adequacy, weak for cardiovascular and depression associations. That posture is the whole point of the platform. We don't prescribe, we describe, and on a topic as overclaimed as MTHFR and folate metabolism, the description is the work.

You can also look at the rs1801133 variant page directly. It walks through the same evidence with citations. We're more conservative than most other interpretation services on MTHFR specifically, because the gap between what the studies actually show and what gets claimed about MTHFR online is one of the larger ones in consumer genomics, and we'd rather underclaim and have it right than over-recommend supplements that don't change clinical outcomes. No wellness washing, no methylation-stack upsell, just the evidence and the gaps.

Want updates when we ship new variant pages or a research deep-dive? Read the latest issue or get notified about early access.